Vysis aims to raise up to $52 million in flotation
This article was originally published in Clinica
Executive Summary
Genomic diagnostics company Vysis plans to raise $45-52 million in an initial public offering which is expected to take place in early February. The US company will offer 3.5 million shares at between $13 and $15 each.